A Bengali-language post raises the idea that GLP-1 drugs might slow aging and add healthy years, with details left to the comments.
Recap by typeshit. Post by @america_bangla on Instagram.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Polskie Radio covers the next wave of weight loss drugs, with retatrutide and CagriSema named. Few details were available beyond the topic itself.
An unsourced alert says compounded injectables, sermorelin included, face scrutiny over sterility. It names no regulator or official action.
Loading…